Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.

Isolation and identification of cancer stem-like cells from murine melanoma cell lines.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.

Cancer stem cell heterogeneity in hereditary breast cancer.

Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.

Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells.

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma.

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.

Identification of pancreatic cancer stem cells.

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.

Molecular definition of breast tumor heterogeneity.